CO58 Long-Term Health Outcomes in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for 1 Year

Abstract

Long-term safety and efficacy of the long-acting injectable antipsychotic aripiprazole lauroxil (AL) in patients with schizophrenia previously were reported based on a phase 3, 52-week, open-label extension (OLE; NCT01626456). The objective of this prespecified analysis was to assess health outcomes using the EuroQol Group Health Outcome Measure-five level (EQ-5D-5L) in patients who remained on AL for up to 1 year.